Lead Product(s) : Amitriptyline
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Preclinical
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
AlgoTherapeutix Announces Orphan Drug Designation Granted by FDA for ATX01 in Erythromelalgia
Details : U.S. Food and Drug Administration (FDA) has granted ATX01 (proprietary topical amitriptyline) Orphan Drug Designation for the treatment of erythromelalgia. The ATX01 program primarily targets Chemotherapy-Induced Peripheral Neuropathy.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 08, 2020
Lead Product(s) : Amitriptyline
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Preclinical
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Amitriptyline
Therapeutic Area : Neurology
Study Phase : Phase III
Sponsor : Cristalia Produtos Quimicos Farma. Ltda
Deal Size : Inapplicable
Deal Type : Inapplicable
Treatment of Neuropathic Pain in Leprosy
Details : Amitriptyline is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Neuralgia.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 27, 2017
Lead Product(s) : Amitriptyline
Therapeutic Area : Neurology
Highest Development Status : Phase III
Sponsor : Cristalia Produtos Quimicos Farma. Ltda
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Amitriptyline
Therapeutic Area : Neurology
Study Phase : Undisclosed
Sponsor : Migraine Research Foundation
Deal Size : Inapplicable
Deal Type : Inapplicable
Prediction of Migraine Prevention Efficacy Based on Individual's Pain Modulation
Details : Amitriptyline is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of Migraine Disorders.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 02, 2014
Lead Product(s) : Amitriptyline
Therapeutic Area : Neurology
Highest Development Status : Undisclosed
Sponsor : Migraine Research Foundation
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Amitriptyline
Therapeutic Area : Neurology
Study Phase : Undisclosed
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Amitriptyline is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of Migraine Disorders.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 13, 2010
Lead Product(s) : Amitriptyline
Therapeutic Area : Neurology
Highest Development Status : Undisclosed
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
